Sleep Movement Disorders Market

By Drug Class;

Benzodiazepines, Opioids, Dopaminergic Agonists, Anticonvulsants, and Others.

By Indication;

Insomnia and Sleep Apnea

By Distribution Channel;

Hospital Pharmacy and Retail Pharmacy

By Types Of Sleep Movement Disorders;

Restless Legs Syndrome, Periodic Limb Movement Disorder (PLMD), Sleep Leg Cramps, Sleep Rhythmic Movement, and Sleep Bruxism.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn629225226 Published Date: June, 2025 Updated Date: August, 2025

Sleep Movement Disorders Market Overview

Sleep Movement Disorders Market (USD Million)

Sleep Movement Disorders Market was valued at USD 1159.17 million in the year 2024. The size of this market is expected to increase to USD 1742.97 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.


Sleep Movement Disorders Market

*Market size in USD million

CAGR 6.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.0 %
Market Size (2024)USD 1159.17 Million
Market Size (2031)USD 1742.97 Million
Market ConcentrationMedium
Report Pages399
1159.17
2024
1742.97
2031

Major Players

  • Cardinal Health, Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Apotex Corporation
  • Egalet Corporation
  • Allergan plc
  • Pfizer Inc.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Sleep Movement Disorders Market

Fragmented - Highly competitive market without dominant players


The Sleep Movement Disorders Market is expanding as awareness increases around conditions like restless leg syndrome and periodic limb movement disorder. With around 65% of specialized clinics adopting targeted monitoring and therapeutic systems, demand is growing for more effective interventions. This momentum is driving innovation and market expansion supported by clinical cooperation and research-driven design.

Technological Upgrades in Monitoring and Therapy
Nearly 62% of technology developers are focused on upgrading movement tracking devices and therapy tools with features like motion-triggered response systems, wearables, and continuous feedback monitoring. These are key technological advancements enabling more responsive care. Active partnerships between device manufacturers and clinical researchers are enabling faster rollouts of smart and personalized solutions.

Collaborative Programs Boosting Clinical Inclusion
Through joint programs and collaborative trials, adoption of movement disorder tools has risen by about 59%. These cross-disciplinary collaborations between sleep clinics, technology developers, and support networks help deliver customized care plans and increase treatment reach. Such integration drives consistent growth through specialized therapeutic inclusion.

Smart Therapies and Future Direction
Looking ahead, nearly 70% of upcoming tools will include smart capabilities, such as adaptive feedback algorithms, integrated mobile support, and automated therapy adjustment based on sleep data. The future outlook for the market is positive, built upon technological evolution and coordinated innovation, setting the stage for advanced care of sleep-related movement disorders.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Indication
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Types Of Sleep Movement Disorders
    5. Market Snapshot, By Region
  4. Sleep Movement Disorders Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing sleep disorder cases globally
        2. Primary healthcare integrating sleep disorder management
        3. Growing awareness of sleep's impact on health
        4. Advanced diagnostic technologies
      2. Restraints
        1. Stigma and misconceptions
        2. Patient adherence challenges
        3. Lifestyle impacts like shift work
      3. Opportunities
        1. Personalized medicine development
        2. Telemedicine expansion
        3. AI-driven diagnostics
        4. Holistic management approaches
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Sleep Movement Disorders Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Benzodiazepines
      2. Opioids
      3. Dopaminergic Agonists
      4. Anticonvulsants
      5. Others
    2. Sleep Movement Disorders Market, By Indication, 2021 - 2031 (USD Million)

      1. Insomnia

      2. Sleep Apnea

    3. Sleep Movement Disorders Market, By Distribution Channel, 2021 - 2031 (USD Million)

      1. Hospital Pharmacy

      2. Retail Pharmacy

    4. Sleep Movement Disorders Market, By Types Of Sleep Movement Disorders, 2021 - 2031 (USD Million)
      1. Restless Legs Syndrome
      2. Periodic Limb Movement Disorder (PLMD)
      3. Sleep Leg Cramps
      4. Sleep Rhythmic Movement
      5. Sleep Bruxism
    5. Sleep Movement Disorders Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape Analysis
    1. Company Profiles
      1. Cardinal Health, Inc.
      2. Mylan N.V.
      3. Teva Pharmaceutical Industries Ltd.
      4. Apotex Corporation
      5. Egalet Corporation
      6. Allergan plc
      7. Pfizer Inc.
  7. Analyst Views
  8. Future Outlook of the Market